Jump directly to page content
Link to homepage GARBE Institutional Capital
Hamburg

Dr. Nadine Galandi and Dr. Dirk Scholl bolster GARBE Institutional Capital’s Science & Tech expertise

GARBE Institutional Capital is strengthening its expertise in Science & Technology Real Estate with the addition of Senior Advisors Dr. Nadine Galandi and Dr. Dirk Scholl. Both are proven specialists within the life science and healthcare areas and will support GARBE Institutional Capital as expert advisors for the development of strategies and concepts for the company’s pan-European Science & Tech platform. Both will work closely with the team led by Managing Director Dr. Thomas Kallenbrunnen and Senior Investment and Fund Manager Remco van der Mije.

Dr. Nadine Galandi (43), a doctor of biochemistry, is currently senior director in the life sciences team at Capgemini Invest. She has previously served the life science and healthcare sector in various positions, including as director and head of digital solutions at Bode Chemie GmbH, a company of the Hartmann Group, and as senior manager and director at Deloitte Consulting.

Dr. Dirk Scholl (49), a medical doctor, is an independent consultant to companies and start-ups in the fields of life sciences and biotechnology, particularly laboratory and medical technology. Among his wide-ranging activities, he supports his clients in M&A processes, financial planning and acquisition due diligence. Dr. Dirk Scholl previously worked for eight years as commercial director of Dynamic Biosensors GmbH, a spin-off from the Technical University of Munich. In addition to his M.D. degree (University of Heidelberg and Mayo Clinic, Rochester, Minnesota), he also holds a Master’s Degree in Business Administration from the Wharton School at the University of Pennsylvania.

“A deep understanding of the users and their needs is essential in Science & Technology Real Estate,” says Remco van der Mije. “Dr. Nadine Galandi and Dr. Dirk Scholl are deeply rooted in their fields of expertise and speak the language of our target group. Together, we will develop tailor-made solutions for our users, thus benefitting our investors.”

"We are firmly convinced that science and technology companies will decisively shape the future of our society in the coming decade,” adds Thomas Kallenbrunnen, Managing Director of GARBE Institutional Capital. “With expert advisors like Dr. Nadine Galandi and Dr. Dirk Scholl, we are deeply embedded in this sector. Having in-house experience like this is a key prerequisite for anticipating the needs of our users and driving the growth of our fund platform.”

Media contact

Meike Neufeld
Feldhoff & Cie. GmbH

+49 175 323 0423
mn@feldhoff-cie.de

Links to social networks